Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data

Preliminary data from a late-stage trial of Alnylam’s RNAi therapy for ATTR amyloidosis with cardiomyopathy appear strong, but details expected later this summer are critical.